Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.
about
Role of Hedgehog Signaling Pathway in NASHMolecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advancesUtilization of animal models to investigate non-alcoholic steatohepatitis-associated hepatocellular carcinomaHepatocellular carcinoma and non-alcoholic steatohepatitis: The state of playAdvances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinomaHepatocellular carcinoma in patients with non-alcoholic fatty liver diseaseHepatocellular carcinoma: a reviewSuccinct guide to liver transplantation for medical studentsNASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed?Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisHepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management.NAFLD and liver transplantation: Current burden and expected challenges.Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease.Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials.Early Intervention With Live Donor Liver Transplantation Reduces Resource Utilization in NASH: The Toronto ExperienceHepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans.Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cellsInhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease developmentAssociation between serum alpha-fetoprotein levels and fatty liver disease: a cross-sectional studySerum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.Current and Future Burden of Chronic Nonmalignant Liver DiseaseBiomarkers of NAFLD progression: a lipidomics approach to an epidemic.Micro RNAs in the development of non-alcoholic fatty liver disease.Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma.Hepatitis C virus-induced hepatocellular carcinomaPTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesisPersonalized management of hepatocellular carcinoma based on molecular information: future prospects.Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases.Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluationThe Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis.Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list.Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival.Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up studyOverexpression of variant PNPLA3 gene at I148M position causes malignant transformation of hepatocytes via IL-6-JAK2/STAT3 pathway in low dose free fatty acid exposure: a laboratory investigation in vitro and in vivo.Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint WorkshopNAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD.Body Roundness Index and Waist-to-Height Ratio are Strongly Associated With Non-Alcoholic Fatty Liver Disease: A Population-Based Study.Medical Management of Metabolic Complications of Liver Transplant Recipients.
P2860
Q26743373-48BEC0D1-965A-418F-ADD3-5CEE6A32A0E0Q26745338-DB87624E-FEC8-4F4C-9A16-6DE76AC5FB26Q26748807-D1DC0CD1-4B8D-4035-A41F-91BDC6751AB9Q26764911-7328FA91-8C8C-408B-BD22-CA63D6238BACQ26795529-C552C6CB-9877-49D0-9D14-ACD38104BB50Q28066100-00A4BC3D-B6CB-43F0-9F11-281DE667401BQ28069290-A386BB90-7DB6-4BA3-BF09-A910A7C1941DQ28075352-6A698EA3-DFA8-4981-AD07-1724DACD6242Q28079900-FD7285DD-2422-4741-8723-A69E0D315312Q28607750-BA29A6BA-76E5-4C78-A4F4-B00BDB3B5E14Q30234574-86D47C75-A86D-4328-9FB7-0243F40ABC6AQ30248646-DDDF39D9-A7DF-4CB7-899C-EDEF1840588EQ30364309-B933B883-34FE-4877-B488-CFB886B7A9ACQ30375036-E0404512-8F24-458E-8EEC-C31AB760C445Q30396916-0274DF43-C578-40C2-9FD3-31E0C91B7BCFQ33779040-B215EDB8-445B-480C-8D19-6A5DF64C4FCFQ33794679-60334520-2C2A-4B07-A839-A91165AB23E6Q33807881-B1559F88-8A01-4650-AD23-7BFDED729AD4Q33914071-4C93B32D-8DFE-41AE-841F-5AD9CCB59ABBQ34137427-77C644DC-FF68-4448-9A52-543ADF3A7AFAQ34207845-48BBB749-C272-4B0C-B44F-BE9EECD4DA18Q34303001-941C3644-3762-4345-9B04-6E1C3B672240Q34490300-BF59FC27-CD16-42EF-86B2-76D08045E0F2Q35120968-AD84EB7A-6252-45CD-81F3-AB9134F9E698Q35127045-F2AE8527-5FA0-407A-A0D4-AC5C00A5ABA1Q35531154-FFBE8787-9F80-4A64-B1E9-00DE47BE4862Q35824057-043A5C37-6709-4A46-8B67-1B326E1A0F76Q35832384-E5599858-7085-4092-93B6-5C2C5B386D28Q35881575-978F5889-E7C5-4C9A-92BB-6397410EDBFFQ35972690-7EFDFBED-F3AA-47FB-A317-A6D9AFB38F30Q36062584-A3969275-A8F9-492B-A5E0-5584BDFA74A3Q36329899-B98C663A-5DF4-46B0-8F29-80E7F3385B55Q36654125-78BDE903-B79A-48AF-814A-86A3979D3D56Q36673799-9C741C9C-FF7F-4B23-BDEE-C7F21C570590Q36747541-7560A99F-5AD3-4E5C-9456-1369197F02F0Q36878525-9B9FF643-49BB-45DF-B5AD-145B42DD47E7Q36987260-116BAB91-979D-47CF-9E93-4C2969B2B7E4Q37174492-1B1C76F2-1559-434F-BC47-875AF1DE273EQ37387559-7F3DDE48-609E-4BD8-AE1D-566634AF4A43Q37421526-B4F97F06-99DA-4572-B980-8926E5859D6C
P2860
Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Nonalcoholic steatohepatitis i ...... cellular carcinoma in the U.S.
@en
Nonalcoholic steatohepatitis i ...... cellular carcinoma in the U.S.
@nl
type
label
Nonalcoholic steatohepatitis i ...... cellular carcinoma in the U.S.
@en
Nonalcoholic steatohepatitis i ...... cellular carcinoma in the U.S.
@nl
prefLabel
Nonalcoholic steatohepatitis i ...... cellular carcinoma in the U.S.
@en
Nonalcoholic steatohepatitis i ...... cellular carcinoma in the U.S.
@nl
P2093
P2860
P921
P356
P1433
P1476
Nonalcoholic steatohepatitis i ...... cellular carcinoma in the U.S.
@en
P2093
Aijaz Ahmed
Ramsey Cheung
Robert J Wong
P2860
P304
P356
10.1002/HEP.26986
P407
P577
2014-04-25T00:00:00Z